Stifel maintains American Well at Hold, raises price target to $12 from $11

Stifel kept its Hold rating on American Well but raised its price target to $12 from $11, suggesting a 5.8% downside from the Nov 3 close of $12.74.

Original reporting
Published Nov 4, 2026, 11:57 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 12:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Stifel maintains American Well at Hold, raises price target to $12 from $11 — source image
Decision brief

The 30-second read

$AMWLNeutralLow
01

Why it matters

The price target raise signals modest confidence but may not move the stock significantly given current pricing.

02

Market read

A small analyst rating update with limited immediate trading impact.

03

What to watch

Potential regulatory changes in telehealth reimbursement could outweigh the modest target raise.

Relevance 5/10Novelty 5/10Timing: today

Background

American Well (Amwell) is a telehealth platform provider; analyst coverage influences investor perception.

Company-level read

Ticker impact

$AMWLNeutralMedium confidence
Context

Stifel raised its price target for American Well to $12 from $11, a new analyst rating change.

Expected impact

potential slight downside as the stock trades above the new target.

Evidence & confidence

The target increase is modest and the stock is already above it, limiting upside.

Market effects

Minor impact on the telehealth sector; analyst upgrades may slightly lift peer sentiment.

U.S. market only; no broader regional effect.

Limited global relevance.

Counterpoint

The upgrade may be premature if earnings miss expectations, leading to a pullback.

Key entities

  • Stifel

    Equity research firm that issued the rating change.

  • American Well

    Telehealth services provider.

Related articles

$AMWLMed

American Well Corp (AMWL) Q3 2026 Earnings Call Highlights: Revenue Beat, Raised Guidance

American Well Corp (AMWL) reported Q3 2026 revenue of $49M, down 12.9% YoY. Subscription revenue fell 22.5% due to churn. Platform visits dropped 30.5% YoY. The VA letter of intent is non-binding, and the DHA contract conversion is pending. CEO Dr. Ido Schoenberg expressed optimism about negotiations and potential growth opportunities. The company expects Q4 adjusted EBITDA breakeven and raised guidance.

$AMWLMedAI 8/10

What American Well (AMWL) Said on Its Q3 Earnings Call

Amwell (AMWL) reported Q3 earnings with virtual primary care visits up 41% YoY, but total platform visits down 30.5%. Gross profit was $26M with a 53% margin. Q4 revenue is forecasted at $48M-$50M, with adjusted EBITDA expected to break even or turn positive. The company raised its full-year 2026 outlook, now expecting revenue of $204M-$206M and a reduced adjusted EBITDA loss. Amwell also discussed potential government contracts, including a nonbinding letter of intent from the VA.

$AMWLHigh

American Well Corp (AMWL): AMWELL® ANNOUNCES RESULTS FOR THE third QUARTER 2026

American Well Corp (AMWL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AMWELL® ANNOUNCES RESULTS FOR THE third QUARTER 2026 BOSTON, November 3 , 2026 –Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the third quarter ended September 30,

$AMWLMedAI 8/10

American Well (AMWL) Q2 2026 Earnings Call Transcript

American Well (AMWL) reported Q2 2026 revenue of $52 million, down 26.6% year over year, with subscription revenue of $25.7 million and AMG revenue of $24.4 million. Adjusted EBITDA loss was $1.15 million and net loss was $9.6 million. Full-year guidance was narrowed to $200-$205 million revenue and improved adjusted EBITDA loss to $9-$7 million. The Defense Health Agency issued an intent to award a sole-source contract.